Anthem Blue Cross and Blue Shield | Medicare AdvantageJune 17, 2025
Specialty pharmacy precertification list expansion — key updates
Effective for dates of service on and after October 1, 2025, the specialty Medicare Part B drug listed in the table below will be included in our precertification review process.
Federal and state laws, along with state contract language and CMS guidelines — including definitions and specific contract provisions or exclusions — take priority over these precertification rules and must be considered first when determining coverage.
Note: Ensuring compliance with the new requirements will help facilitate claim approval.
HCPCS or CPT® codes | Medicare Part B drugs |
J3590 | Alhemo (concizumab‑mtci) |
C9399, J9999 | Datroway (datopotamab deruxtecan‑dlnk) |
C9399, J9999 | Grafapex (treosulfan) |
C9399, J9999 | Opdivo Qvantig (nivolumab hyaluronidase‑nvhy) |
C9399, J3590 | Steqeyma (ustekinumab‑stba) |
C9399, J9999 | Unloxcyt (cosibelimab‑ipdl) |
J3590 | Yesintek (ustekinumab‑kfce) |
C9302 | Ziihera (zanidatamab‑hrii) |
Anthem Blue Cross and Blue Shield is the trade name of Anthem Health Plans of Virginia, Inc. Anthem Blue Cross and Blue Shield, and its affiliate HealthKeepers, Inc., serving all of Virginia except for the City of Fairfax, the Town of Vienna, and the area east of State Route 123, are independent licensees of the Blue Cross Blue Shield Association. Anthem is a registered trademark of Anthem Insurance Companies, Inc.
MULTI-BCBS-CR-082709-25-CPN81629
PUBLICATIONS: July 2025 Provider Newsletter
To view this article online:
Or scan this QR code with your phone